The NC1 domain of type XIX collagen inhibits melanoma cell migration
- PMID: 20840910
- DOI: 10.1684/ejd.2010.1070
The NC1 domain of type XIX collagen inhibits melanoma cell migration
Abstract
Type XIX collagen is a minor collagen that localizes to basement membrane zones. We previously demonstrated that the C-terminal NC1 domain of type XIX collagen inhibits tumor growth in vivo. In the present study, we analyzed the effects of the NC1(XIX) collagen domain on migratory behaviour of melanoma B16F10 cells. We found that NC1(XIX) do not inhibit melanoma cell proliferation. On the contrary, NC1(XIX) strongly inhibited the migratory capacities of melanoma cells in the scratch wound model and in Ibidi® devices: cell migration speed was 7.69 ± 1.49 μm/h for the controls vs 6.64 ± 0.82 μm/h for cells incubated with 30 μmol/L NC1(XIX) and 5.72 ± 0.67 μmol/h with 60 μmol/L NC1(XIX). Similar results were obtained with UACC 903 human melanoma cells. Further work will be necessary to elucidate the molecular mechanisms of this migration inhibition. It may, however, explain, at least partially, the inhibition of tumor growth that we observed in vivo.
Similar articles
-
The anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through αvβ3 integrin interaction.Oncotarget. 2016 Jan 12;7(2):1516-28. doi: 10.18632/oncotarget.6399. Oncotarget. 2016. PMID: 26621838 Free PMC article.
-
Plasmin releases the anti-tumor peptide from the NC1 domain of collagen XIX.Oncotarget. 2015 Feb 28;6(6):3656-68. doi: 10.18632/oncotarget.2849. Oncotarget. 2015. PMID: 25668817 Free PMC article.
-
The NC1 domain of type XIX collagen inhibits in vivo melanoma growth.Mol Cancer Ther. 2007 Feb;6(2):506-14. doi: 10.1158/1535-7163.MCT-06-0207. Mol Cancer Ther. 2007. PMID: 17308049
-
Control of melanoma cell invasion by type IV collagen.Cancer Detect Prev. 2005;29(3):260-6. doi: 10.1016/j.cdp.2004.09.003. Epub 2004 Nov 23. Cancer Detect Prev. 2005. PMID: 15936594 Review.
-
Type XIX collagen: A new partner in the interactions between tumor cells and their microenvironment.Matrix Biol. 2017 Jan;57-58:169-177. doi: 10.1016/j.matbio.2016.07.010. Epub 2016 Aug 1. Matrix Biol. 2017. PMID: 27491275 Review.
Cited by
-
F4, a collagen XIX-derived peptide, inhibits tumor angiogenesis through αvβ3 and α5β1 integrin interaction.Cell Adh Migr. 2021 Dec;15(1):215-223. doi: 10.1080/19336918.2021.1951425. Cell Adh Migr. 2021. PMID: 34308743 Free PMC article.
-
Type XIX collagen: a promising biomarker from the basement membranes.Neural Regen Res. 2020 Jun;15(6):988-995. doi: 10.4103/1673-5374.270299. Neural Regen Res. 2020. PMID: 31823868 Free PMC article. Review.
-
The FKBPL-based therapeutic peptide, AD-01, protects the endothelium from hypoxia-induced damage by stabilising hypoxia inducible factor-α and inflammation.J Transl Med. 2025 Mar 11;23(1):309. doi: 10.1186/s12967-025-06118-w. J Transl Med. 2025. PMID: 40069829 Free PMC article.
-
The anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through αvβ3 integrin interaction.Oncotarget. 2016 Jan 12;7(2):1516-28. doi: 10.18632/oncotarget.6399. Oncotarget. 2016. PMID: 26621838 Free PMC article.
-
Plasmin releases the anti-tumor peptide from the NC1 domain of collagen XIX.Oncotarget. 2015 Feb 28;6(6):3656-68. doi: 10.18632/oncotarget.2849. Oncotarget. 2015. PMID: 25668817 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical